☰

Global Therapeutic Plasma Exchange Market

Report ID : 1120 | Published : 2022-08-16 | Pages: 140 | Format:

Share

Plasma exchange is a biological procedure that removes large-molecular-weight substances such as harmful antibodies from the plasma. In this procedure, a large portion of plasma containing abnormal matter and toxins are removed from the components of WBCs, RBCs, and platelets and then replaced with replacement fluid, like fresh frozen plasma (FFP) i.e., donor plasma or albumin. It is performed to treat several chronic diseases as the first-line or as second line of treatment therapy in neurological and non-neurological conditions.

Therapeutic plasma exchange (TPE) can rapidly decrease plasma viscosity. Thus, it can improve patient outcomes in critically ill patients with COVID-19 by reducing plasma viscosity and thereby enhancing blood flow.

Global Therapeutic plasma exchange market is expected to offer the lucrative growth in the near future due to the rising prevalence of chronic diseases and ongoing research and clinical trials to determine the efficacy of plasma exchange over other treatments. Also, the outbreak of a new viral disease, COVID – 19, is also creating a massive demand for therapeutic plasma exchange and thereby drive the global market.

The Global Therapeutic plasma exchange market is segmented on the basis of product & technologies, end-users, and region. Based on the base of product and technology, the market is divided into the product (consumables & devices) and technology (centrifugation & membrane separation). On the basis of indication, the market is divided into neurological disorders, hematology disorders, renal disorders, and metabolic disorders. On the basis of end-users, the market is divided into blood collection centres & blood component providers, hospitals & transfusion centres, and other end users. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. North America accounted for the largest share of the market in 2019, followed by Europe and Asia Pacific. On the other hand, the Asia Pacific is projected to have the highest growth rate during the forecast period.

The key players of this market include Terumo BCT, Inc., Fresenius SE & Co. KGaA, Haemonetics Corporation, Asahi Kasei Medical Co. Ltd., B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, Kaneka Corporation, Kawasumi Laboratories, Inc., Nikkiso Co., Ltd., Miltenyi Biotec, Medica S.p.A., Medicap Clinic GmbH, Infomed among others.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Therapeutic Plasma Exchange Market Snapshot

Chapter 4. Global Therapeutic Plasma Exchange Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Penetration & Growth Prospect Mapping

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Products & Technology Advancement in Ambulatory Mammography

Chapter 5. Market Segmentation 1: Products & Technology Estimates & Trend Analysis

5.1. Products & Technology & Market Share, 2020 & 2028

5.2. Market Size (Value) & Forecasts and Trend Analyses, 2020 to 2028 for the following Products & Technology:

5.2.1. Product

 Consumables

 Devices

5.2.2. Technology

 Centrifugation

 Membrane Separation

Chapter 6. Market Segmentation 1: Indications & Trend Analysis

6.1. Indications & Market Share, 2020 & 2028

6.2. Market Size (Value)& Forecasts and Trend Analyses, 2020 to 2028 for the following Indications:

6.2.1. Neurological Disorders

 Guillain–Barré syndrome

 Chronic inflammatory demyelinating polyneuropathy

 Myasthenia gravis

 Multiple sclerosis

 PANDASa

6.2.2. Hematology Disorders

 Thrombotic thrombocytopenic purpura

 Atypical haemolytic uraemic syndrome

 Hyperviscosity syndromes

 Severe/symptomatic cryoglobulinaemia

6.2.3. Renal Disorders

 Goodpasture’s syndrome

 Wegener’s glomerulonephritis

 Antibody-mediated renal transplant rejection

6.2.4. Metabolic Disorders

 Familial hypercholesterolaemia (homozygous)

6.2.5. Other Indications

Chapter 7. Market Segmentation 1: End-Users & Trend Analysis

7.1. End-Users & Market Share, 2020 & 2028

7.2. Market Size (Value)& Forecasts and Trend Analyses, 2020 to 2028 for the following End-Users

7.2.1. Blood Collection Centres & Blood Component Providers

7.2.2. Hospitals & Transfusion Centres

7.2.3. Other End Users

Chapter 8. Therapeutic Plasma Exchange Market Segmentation 3: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts Products & Technology, 2020-2028

8.1.2. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2020-2028

8.1.3. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2020-2028

8.1.4. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by country, 2020-2028

8.1.4.1. U.S.

8.1.4.2. Canada

8.2. Europe

8.2.1. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2020-2028

8.2.2. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2020-2028

8.2.3. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2020-2028

8.2.4. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2020-2028

8.2.4.1. Germany

8.2.4.2. Poland

8.2.4.3. France

8.2.4.4. Italy

8.2.4.5. Spain

8.2.4.6. UK

8.2.4.7. Rest of Europe

8.3. Asia Pacific

8.3.1. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2020-2028

8.3.2. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2020-2028

8.3.3. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2020-2028

8.3.4. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2020-2028

8.3.4.1. China

8.3.4.2. India

8.3.4.3. Japan

8.3.4.4. Australia

8.3.4.5. Rest of Asia Pacific

8.4. Latin America

8.4.1. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2020-2028

8.4.2. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2020-2028

8.4.3. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2020-2028

8.4.4. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2020-2028

8.4.4.1. Brazil

8.4.4.2. Rest of Latin America

8.5. MEA

8.5.1. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts Products & Technology, 2020-2028

8.5.2. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2020-2028

8.5.3. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2020-2028

8.5.4. MEA revenue Therapeutic Plasma Exchange Market revenue (US$ Million) by country, (US$ Million) 2020-2028

8.5.4.1. South Africa

8.5.4.2. Rest of MEA

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. TERUMO BCT, INC.

9.2.2. FRESENIUS SE & CO. KGAA

9.2.3. HAEMONETICS CORPORATION

9.2.4. BAXTER INTERNATIONAL INC.

9.2.5. ASAHI KASEI MEDICAL CO. LTD.

9.2.6. BRAUN MELSUNGEN AG

9.2.7. CERUS CORPORATION

9.2.8. KANEKA CORPORATION

9.2.9. KAWASUMI LABORATORIES, INC.

9.2.10. NIKKISO CO., LTD.

9.2.11. MILTENYI BIOTEC

9.2.12. Other Prominent Players

Global Therapeutic Plasma Exchange Market Segmentation:

Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Product & Technology, 2019-2030

  • Product
    • Consumables
    • Devices
  • Technology
    • Centrifugation
    • Membrane Separation

Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), By Indication, 2019-2030

  • Neurological Disorders: Guillain–Barré syndrome, Chronic inflammatory demyelinating polyneuropathy, Myasthenia gravis, Multiple sclerosis and PANDASa
  • Hematology Disorders: Thrombotic, thrombocytopenic purpura, Atypical haemolytic uraemic syndrome, Hyperviscosity syndromes and Severe/symptomatic cryoglobulinaemia
  • Renal Disorders: Goodpasture’s syndrome, Wegener’s glomerulonephritis and Antibody-mediated renal transplant rejection
  • Metabolic Disorders: Familial hypercholesterolaemia (homozygous)
  • Other Indications

Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), By End Users, 2019-2030

  • Blood Collection Centres & Blood Component Providers
  • Hospitals & Transfusion Centres
  • Other End Users

Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), By Region, 2019-2030

North America Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country, 2019-2030

  • U.S.
  • Canada

Europe Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country, 2019-2030

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country, 2019-2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country, 2019-2030

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country, 2019-2030

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3786
$10000
$10000
Related Reports
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals
Review Request

We’ll review your request & send a personalized quote for cost and time needed
Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..

Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.

Category
Quick Links
Office Address